Clinical and Laboratory Findings of 12 Children with Invasive Meningococcal Disease in Pediatric Intensive Care Unit.
Journal
Critical care research and practice
ISSN: 2090-1305
Titre abrégé: Crit Care Res Pract
Pays: Egypt
ID NLM: 101539357
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
04
2021
revised:
28
06
2021
accepted:
29
08
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
17
9
2021
Statut:
epublish
Résumé
Invasive meningococcal disease (IMD) is a serious infectious disease requiring stay in a pediatric intensive care unit (PICU) that continues to be associated with high morbidity and mortality rates. Prompt recognition, early antibiotic therapy, and aggressive supportive therapies can reduce mortality. We aimed to assess the clinical and laboratory characteristics of children with IMD. We followed up 12 patients (five girls and seven boys, 5-168 months of age, and four below one year of age) with IMD (nine patients have meningococcemia with meningitis, and three patients have meningococcemia) in PICU. All children were previously healthy and have not received meningococcal vaccines. Their pediatric risk of mortality (PRISM) scores varies between 5 and 37, four of the patients required mechanical ventilation, and the predicted mortality was 39% at admission. Seven patients had catecholamine refractory septic shock and disseminated intravascular coagulation (DIC). Three of the patients required extracorporeal treatment. The predominant serogroup is Men B (5/12). The mortality rate was 16.6% with early use of antibiotics, fluids, and other interventions. Mortality related to IMD is higher among children with severe meningococcemia despite early interventions in PICU. Routine use of meningococcal vaccines during childhood would be a better strategy for controlling IMD in both developing and developed countries.
Identifiants
pubmed: 34527377
doi: 10.1155/2021/9713918
pmc: PMC8435381
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9713918Informations de copyright
Copyright © 2021 Eylem Kiral and Ayse Filiz Yetimakman.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Hum Vaccin Immunother. 2019;15(2):459-469
pubmed: 30273506
Adv Pediatr. 2020 Aug;67:29-46
pubmed: 32591062
mSphere. 2020 Mar 25;5(2):
pubmed: 32213620
PLoS One. 2019 Mar 13;14(3):e0212922
pubmed: 30865671
Vaccine. 2019 May 9;37(21):2768-2782
pubmed: 30987851
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Front Pediatr. 2018 Nov 09;6:321
pubmed: 30474022
J Adolesc Health. 2016 Aug;59(2 Suppl):S21-8
pubmed: 27449146
BMC Pediatr. 2018 Jul 30;18(1):246
pubmed: 30060751
Pediatr Infect Dis J. 2016 Apr;35(4):407-13
pubmed: 26974748
Vaccine. 2018 Jun 18;36(26):3876-3881
pubmed: 29699791
Microorganisms. 2021 Mar 03;9(3):
pubmed: 33802567
Pediatr Infect Dis J. 2014 Jul;33(7):777-9
pubmed: 24622347
Pediatr Rev. 2017 Apr;38(4):158-169
pubmed: 28364047